Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419694 | 1.00 | HTR6 (0.42) | HTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL29939038 | 0.98 | HTR6 (0.41) | HTR6 | |
| Hydrochloric Acid SCHEMBL14324682 | 0.98 | HTR6 (0.41) | HTR6 | |
| SCHEMBL29332338 | 0.83 | HTR6 (0.39) | HTR6HTR2B | |
| SCHEMBL963338 | 0.81 | HTR6 (0.36) | HTR6 | |
| SCHEMBL3387753 | 0.72 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL3418907 | 0.72 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL19863554 | 0.70 | PDE7A (0.33) | HTR6 | |
| SCHEMBL17062800 | 0.69 | HTR2C (0.36) | HTR6HTR2CHTR2B | |
| SCHEMBL718126 | 0.68 | LTA4H (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| EP-4534538-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3808749-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES | VERTEX PHARMA (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-28 | — | — | US | disclosed |
| US-11117900-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3486245-B1 | 2-AMINO-N-(PIPERIDIN-1-YL-PYRIDIN-3-YL) PYRAZOLO[1,5ALPHA]PYRIMIDINE-3-CARBOXAMID AS INHIBITOR OF ATR KINASE | VERTEX PHARMA (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117900-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, TBK1 | HTR6 4367/4885HTR2C 4799/4885HTR2B 4865/4885 |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | HTR6 4339/4885HTR2C 4800/4885HTR2B 4865/4885 |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | HTR6 4367/4885HTR2C 4799/4885HTR2B 4865/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | HTR6 182/4885HTR2C 228/4885HTR2B 245/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | HTR6 100/4885HTR2C 120/4885HTR2B 466/4885 |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, CHEK1 | HTR6 4339/4885HTR2C 4800/4885HTR2B 4865/4885 |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, TBK1 | HTR6 4367/4885HTR2C 4799/4885HTR2B 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.